Blake J Cochran1, William J Ryder2,3, Arvind Parmar4, Shudi Tang5, Anthonin Reilhac3,4, Andrew Arthur4, Arnaud Charil3,4, Hasar Hamze4, Philip J Barter5,6, Leonard Kritharides6,7, Steven R Meikle2,3, Marie-Claude Gregoire4, Kerry-Anne Rye5,6. 1. School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, 2052, NSW, Australia. b.cochran@unsw.edu.au. 2. Faculty of Health Sciences, University of Sydney, Sydney, NSW, Australia. 3. Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia. 4. ANSTO LifeSciences, Sydney, NSW, Australia. 5. School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, 2052, NSW, Australia. 6. Faculty of Medicine, University of Sydney, Sydney, NSW, Australia. 7. Department of Cardiology, Concord Repatriation General Hospital, Sydney, NSW, Australia.
Abstract
AIMS/HYPOTHESIS: Type 2 diabetes is characterised by decreased HDL levels, as well as the level of apolipoprotein A-I (apoA-I), the main apolipoprotein of HDLs. Pharmacological elevation of HDL and apoA-I levels is associated with improved glycaemic control in patients with type 2 diabetes. This is partly due to improved glucose uptake in skeletal muscle. METHODS: This study used kinetic modelling to investigate the impact of increasing plasma apoA-I levels on the metabolism of glucose in the db/db mouse model. RESULTS: Treatment of db/db mice with apoA-I for 2 h significantly improved both glucose tolerance (AUC 2574 ± 70 mmol/l × min vs 2927 ± 137 mmol/l × min, for apoA-I and PBS, respectively; p < 0.05) and insulin sensitivity (AUC 388.8 ± 23.8 mmol/l × min vs 194.1 ± 19.6 mmol/l × min, for apoA-I and PBS, respectively; p < 0.001). ApoA-I treatment also increased glucose uptake by skeletal muscle in both an insulin-dependent and insulin-independent manner as evidenced by increased uptake of fludeoxyglucose ([(18)F]FDG) from plasma into gastrocnemius muscle in apoA-I treated mice, both in the absence and presence of insulin. Kinetic modelling revealed an enhanced rate of insulin-mediated glucose phosphorylation (k 3) in apoA-I treated mice (3.5 ± 1.1 × 10(-2) min(-1) vs 2.3 ± 0.7 × 10(-2) min(-1), for apoA-I and PBS, respectively; p < 0.05) and an increased influx constant (3.7 ± 0.6 × 10(-3) ml min(-1) g(-1) vs 2.0 ± 0.3 × 10(-3) ml min(-1) g(-1), for apoA-I and PBS, respectively; p < 0.05). Treatment of L6 rat skeletal muscle cells with apoA-I for 2 h indicated that increased hexokinase activity mediated the increased rate of glucose phosphorylation. CONCLUSIONS/ INTERPRETATION: These findings indicate that apoA-I improves glucose disposal in db/db mice by improving insulin sensitivity and enhancing glucose phosphorylation.
AIMS/HYPOTHESIS: Type 2 diabetes is characterised by decreased HDL levels, as well as the level of apolipoprotein A-I (apoA-I), the main apolipoprotein of HDLs. Pharmacological elevation of HDL and apoA-I levels is associated with improved glycaemic control in patients with type 2 diabetes. This is partly due to improved glucose uptake in skeletal muscle. METHODS: This study used kinetic modelling to investigate the impact of increasing plasma apoA-I levels on the metabolism of glucose in the db/db mouse model. RESULTS: Treatment of db/db mice with apoA-I for 2 h significantly improved both glucose tolerance (AUC 2574 ± 70 mmol/l × min vs 2927 ± 137 mmol/l × min, for apoA-I and PBS, respectively; p < 0.05) and insulin sensitivity (AUC 388.8 ± 23.8 mmol/l × min vs 194.1 ± 19.6 mmol/l × min, for apoA-I and PBS, respectively; p < 0.001). ApoA-I treatment also increased glucose uptake by skeletal muscle in both an insulin-dependent and insulin-independent manner as evidenced by increased uptake of fludeoxyglucose ([(18)F]FDG) from plasma into gastrocnemius muscle in apoA-I treated mice, both in the absence and presence of insulin. Kinetic modelling revealed an enhanced rate of insulin-mediated glucose phosphorylation (k 3) in apoA-I treated mice (3.5 ± 1.1 × 10(-2) min(-1) vs 2.3 ± 0.7 × 10(-2) min(-1), for apoA-I and PBS, respectively; p < 0.05) and an increased influx constant (3.7 ± 0.6 × 10(-3) ml min(-1) g(-1) vs 2.0 ± 0.3 × 10(-3) ml min(-1) g(-1), for apoA-I and PBS, respectively; p < 0.05). Treatment of L6 rat skeletal muscle cells with apoA-I for 2 h indicated that increased hexokinase activity mediated the increased rate of glucose phosphorylation. CONCLUSIONS/ INTERPRETATION: These findings indicate that apoA-I improves glucose disposal in db/db mice by improving insulin sensitivity and enhancing glucose phosphorylation.
Authors: Brian G Drew; Kerry-Anne Rye; Stephen J Duffy; Philip Barter; Bronwyn A Kingwell Journal: Nat Rev Endocrinol Date: 2012-01-24 Impact factor: 43.330
Authors: Brian R Barnes; Jeffrey W Ryder; Tatiana L Steiler; Lee G D Fryer; David Carling; Juleen R Zierath Journal: Diabetes Date: 2002-09 Impact factor: 9.461
Authors: Karin G Stenkula; Maria Lindahl; Jitka Petrlova; Jonathan Dalla-Riva; Olga Göransson; Samuel W Cushman; Ewa Krupinska; Helena A Jones; Jens O Lagerstedt Journal: Diabetologia Date: 2014-01-18 Impact factor: 10.122
Authors: Bret H Goodpaster; Alessandra Bertoldo; Jason M Ng; Koichiro Azuma; R Richard Pencek; Carol Kelley; Julie C Price; Claudio Cobelli; David E Kelley Journal: Diabetes Date: 2013-11-12 Impact factor: 9.461
Authors: Andreas Mæchel Fritzen; Joan Domingo-Espín; Anne-Marie Lundsgaard; Maximilian Kleinert; Ida Israelsen; Christian S Carl; Trine S Nicolaisen; Rasmus Kjøbsted; Jacob F Jeppesen; Jørgen F P Wojtaszewski; Jens O Lagerstedt; Bente Kiens Journal: Mol Metab Date: 2020-03-04 Impact factor: 7.422